Fusion Antibodies PLC Investor presentation
April 18 2019 - 1:00AM
RNS Non-Regulatory
TIDMFAB
Fusion Antibodies PLC
18 April 2019
Fusion Antibodies plc
("Fusion" or the "Company")
Investor presentation
Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract
research organisation specialising in antibody engineering
services, announces that it will hold a presentation for investors
on Tuesday, 30 April 2019.
The briefing by Dr Paul Kerr, CEO of Fusion, will take place at
Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, London
EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by
drinks and networking. If you would like to register to attend,
please contact Walbrook PR on 020 7933 8780 or email
fusion@walbrookpr.com.
Enquiries:
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Anna Dunphy Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced over 250 antibodies and successfully completed over 100
humanisation projects for its international, blue-chip client base,
which includes eight of the top 10 global pharmaceutical companies
by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. It was initially a drug development business
but revised its operations to focus on CRO work in 2011. The
Company has a highly experienced management team with a combined 47
years' experience in the biopharma industry.
The global monoclonal antibody therapeutics market, which
accounted for 43 per cent. of the global biologics market in 2016,
was valued at between $85.4 billion and $86.7 billion in 2015 and
is forecast to increase at a CAGR of between 8.2 per cent. and 12.2
per cent. for the period 2016 to 2024.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGUQWCUPBGCM
(END) Dow Jones Newswires
April 18, 2019 02:00 ET (06:00 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024